Article
Dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive hairy cell leukemia.
Blood - 2 Mar 2023
Kreitman Robert J, Moreau Philippe, Ravandi Farhad, Hutchings Martin, Gazzah Anas, Michallet Anne-Sophie, Wainberg Zev A, Stein Alexander, Dietrich Sascha, de Jonge Maja J A, Willenbacher Wolfgang, De Grève Jacques, Arons Evgeny, Ilankumaran Palanichamy, Burgess Paul, Gasal Eduard, Subbiah Vivek
Abstract excerpt
BRAF V600E is the key oncogenic driver mutation in hairy cell leukemia (HCL). We report the efficacy and safety of dabrafenib plus trametinib in patients with relapsed/refractory BRAF V600E mutation-positive HCL. This open-label, phase 2 study enrolled patients with BRAF V600E mutation-positive HCL refractory to first-line treatment with a purine analog or relapsed after ≥2 prior lines of treatment. Patients...
Read the complete abstract on PubMedTopics
Share this publication in a Topic to start or enrich a Post.